The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein

Molecular and Cellular Biology

Volumn 18, Issue 6, 1998, Pages 3604-3611

  Lutterbach, Bart ^a   Sun, Daxi ^b   Schuetz, John ^b   Hiebert, Scott W ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CHROMOSOME TRANSLOCATION; DIMERIZATION; GENE REPRESSION; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN;

ANIMALIA;

EID: 0031844689     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.18.6.3604     Document Type: Article

References (50)

1. Arceci, R. J. 1993. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81:2215-2222.
2. Berger, J., J. Hauber, R. Hauber, R. Geiger, and B. R. Cullen. 1988. Secreted placental alkaline phophatase: a powerful new quantitative indicator of gene expression in eukaryotic cells. Gene 66:1-10.
3. Bloomfield, C. D. 1992. Prognostic factors for selecting curative therapy for adult acute myeloid leukemia. Leukemia 6:65-67.
4. Castilla, L. H., C. Wijmenga, Q. Wang, T. Stacy, N. Speck, M. Eckhaus, M. Marin-Padilla, F. S. Collins, A. Wynashaw-Boris, and P. P. Liu. 1996. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MY11 Cell 87:687-696.
5. Chin, K.-V., K. Ueda, I. Pastan, and M. Gottesman. 1992. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255:459-462.
6. Combates, N. J., R. W. Rzepka, Y. N. Chen, and D. Cohen. 1994. NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR-1 promoter. J. Biol. Chem. 269:29715-29719.
7. Cowell, I. 1994. Repression versus activation in the control of gene transcription. Trends Biochem. Sci. 19:38-42.
8. Crook, T., D. Wrede, and K. H. Vousden. 1991. p53 point mutations in HPV negative human cervical carcinoma cell lines. Oncogene 6:873-875.
9. Dastague, N., C. Payen, M. Lafage-Pochitaloff, P. Bernard, D. Leroux, F. Huguet-Rigal, A. M. Stoppa, G. Marit, L. Molina, and M. Michallet. 1995. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia 9:1491-1498.
10. Erickson, P. F., G. Dessev, R. S. Lasher, G. Philips, M. Robinson, and H. A. Drabkin. 1996. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease. Blood 88:1813-1823.
11. Fears, S., M. Gavin, D. E. Zhang, C. Hetherington, Y. Ben-David, J. D. Rowley, and G. Nucifora. 1997. Functional characterization of ETV6 and ETV6/CBFA2 in the regulation of the MCSFR proximal promoter. Proc. Natl. Acad. Sci. USA 94:1949-1954.
12. Feinstein, P. G., K. Kornfeld, D. S. Hogness, and R. S. Mann. 1995. Identification of homeotic target genes in Drosophila melanogaster including nervy, a proto-oncogene homologue. Genetics 140:573-586.
13. Frank, R., J. Zhang, H. Uchida, S. Meyers, S. W. Hiebert, and S. D. Nimer. 1995. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene 11:2667-2674.
14. Friedman, A. D. 1996. Regulation of immature myeloid cell differentiation by PEBP2/CBF, Myb, C/EBP, and Ets family members. Curr. Top. Microbiol. Immunol. 211:149-157.
15. Giese, K., C. Kingsley, J. R. Kirshner, and R. Grosschedl. 1995. Assembly and function of a TCR alpha enhancer complex is dependent on LEF-1-induced DNA bending and multiple protein-protein interactions. Genes Dev. 9:995-1008.
16. Gorman, C. M., L. F. Moffat, and B. H. Howard. 1982. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2:1044-1051.
17. Gross, C. T., and W. McGinnis. 1996. DEAF-1, a novel protein that binds an essential region in a Deformed response element. EMBO J. 15:1961-1970.
18. Herschbach, B. M., and A. D. Johnson. 1993. Transcriptional repression in eukaryotes. Annu. Rev. Cell Biol. 9:479-509.
19. Hiebert, S. W., W. Sun, J. N. Davis, T. Golub, S. Shurtleff, A. Buijs, J. R. Downing, G. Grosveld, M. F. Roussel, D. G. Gilliland, N. Lenny, and S. Meyers. 1996. The t(12;21) translocation converts AML-1B from an activator to a represser of transcription. Mol. Cell. Biol. 16:1349-1355.
20. Hoey, T., R. O. Weinzierl, G. Gill, J. L. Chen, B. D. Dynlacht, and R. Tjian. 1993. Molecular cloning and functional analysis of Drosophila TAF110 reveal properties expected of coactivators. Cell 72:247-260.
21. Joventino, L. P., W. Stock, N. J. Lane, K. M. Daly, R. Mick, M. M. Le Beau, and R. A. Larson. 1995. Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia. Leukemia 9:433-439.
22. Kalwinski, D. K., S. C. Raimondi, M. J. Schell, J. Mirro, V. M. Santana, F. Behm, G. V. Dahl, and D. Williams. 1990. Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia. J. Clin. Oncol. 8:75-83.
23. Kitabayashi, I., K. Ida, F. Morohoshi, A. Yokoyama, N. Mitsuhashi, K. Shimizu, N. Nomura, Y. Hayashi, and M. Ohki. 1998. The AML1-MTG8 leukemic fusion protein forms a complex with a novel member of the MTG8(ETO/CDR) family, MTGR1. Mol. Cell. Biol. 18:846-858.
24. Kunkel, T. A. 1985. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc. Natl. Acad. Sci. USA 82:488-494.
25. Leith, C. P., K. J. Kopecky, J. Godwin, T. McConnel, M. L. Slovak, I.-M. Chen, D. R. Head, F. R. Appelbaum, and C. L. Willman. 1997. Acute myeloid leukemia in the elderly; assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 9:3323-3329.
26. Lenny, N., S. Meyers, and S. W. Hiebert. 1995. Functional domains of the t(8;21) fusion protein. AML-1/ETO. Oncogene 11:1761-1769.
27. Lenny, N., J. J. Westendorf, and S. W. Hiebert. 1997. Transcriptional regulation during myelopoiesis. Mol. Biol. Rep. 24:157-168.
28. Liu, P., S. A. Tarle, A. Hajra, D. F. Claxton, P. Marlton, M. Freedman, M. J. Siciliano, and F. S. Collins. 1993. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 261:1041-1044.
29. Lutterbach, B., and S. W. Hiebert. Unpublished data.
30. Lutterbach, B., J. J. Westendorf, A. Patten, K. Huynh, V. J. Bardwell, R. M. Lavinsky, M. G. Rosenfeld, E. Seto, and S. W. Hiebert. Mechanism of transcriptional repression by the t(8;21) fusion protein: ETO interacts with the N-CoR and mSin3 corepressors. Submitted for publication.
31. Martin, P., and T. Papayannopoulou. 1982. A new human erythroleukemia cell line with spontaneous and induced globin expression. Science 216:1233-1237.
32. Martinez-Climent, J. A., N. J. Lane, C. M. Rubin, E. Morgan, H. S. Johnstone, R. Mick, S. B. Murphy, J. W. Vardiman, R. A. Larson, M. M. Le Beau, and J. D. Rowley. 1995. Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. Leukemia 9:95-101.
33. Meyers, S., J. R. Downing, and S. W. Hiebert. 1993. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol. Cell. Biol. 13:6336-6345.
34. Meyers, S., and S. W. Hiebert. 1995. Indirect and direct disruption of transcriptional regulation in cancer: E2F and AML-1. Crit. Rev. Eukaryot. Gene Expr. 5:365-383.
35. Meyers, S., N. Lenny, and S. W. Hiebert. 1995. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol. Cell. Biol. 15:1974-1982.
36. Meyers, S., N. Lenny, W. Sun, and S. W. Hiebert. 1996. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia. Oncogene 13:303-312.
37. Miyoshi, H., T. Kozu, K. Shimizu, K. Enomoto, N. Maseki, Y. Kaneko, N. Kamada, and M. Ohki. 1993. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 12:2715-2721.
38. Miyoshi, H., K. Shimizu, T. Kou, N. Maseki, Y. Kaneko, and M. Ohki. 1991. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML. Proc. Natl. Acad. Sci. USA 88:10431-10434.
39. Norton, P. A., and J. M. Coffin. 1985. Bacterial B-galactosidase as a marker of Rous sacoma virus gene expression and replication. Mol. Cell. Biol. 5:281-290.
40. Okuda, T., J. van Deursen, S. W. Hiebert, G. Grosveld, and J. R. Downing. 1996. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84:321-330.
41. Pearson, L., C. P. Leith, M. H. Duncan, I. M. Chen, T. McConnell, K. Trinkaus, K. Foucar, and C. L. Willman. 1996. Multidrug resistance-1 (MDR1) expression and functional dye/drug efflux is highly correlated with the t(8;21) chromosomal translocation in pediatric acute myeloid leukemia. Leukemia 10:1274-1282.
42. Pietenpol, J. A., T. Tokino, S. Thiagalingam, W. S. el-Deiry, K. W. Kinzler, and B. Vogelstein. 1994. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. USA 91:1998-2002.
43. Porwit-MacDonald, A., G. Janossey, K. Ivory, D. Swirsky, R. Peters, K. Wheatley, H. Walker, A. Turker, A. H. Goldstone, and A. Burnett. 1996. Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). Blood 87:1162-1169.
44. Schuetz, J. Unpublished data.
45. Shurtleff, S. A., A. Buijs, F. G. Behm, J. E. Rubnitz, S. C. Raimondi, M. L. Hancock, G. C. Chan, C. H. Pui, G. Grosveld, and J. R. Downing. 1995. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 9:1985-1989.
46. Thottassery, J. V., G. P. Zambetti, D. Arimori, E. G. Schuetz, and J. D. Schuetz. 1997. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc. Natl. Acad. Sci. USA 94:11037-11042.
47. Uchida, H., J. Zhang, and S. D. Nimer. 1997. Am11a and Am11b can transactivate the human Il-3 promoter. J. Immunol. 158:2251-2258.
48. Wang, Q., T. Stacy, J. D. Miller, A. F. Lewis, T.-L. Gu, X. Huang, J. H. Bushweller, J.-C. Bories, F. W. Alt, G. Ryan, P. P. Liu, A. Wynshaw-Boris, M. Binder, M. Marin-Padilla, A. H. Sharpe, and N. A. Speck. 1996. The CBFβ subunit is essential for CBFα2 (AML1) function in vivo. Cell 87:697-708.
49. Westendorf, J. J., C. M. Yamamoto, N. Lenny, J. R. Downing, M. E. Selsted, and S. W. Hiebert. 1998. The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-α, inhibits C/EBP-a-dependent transcription, and blocks granulocytic differentiation. Mol. Cell. Biol. 18:322-333.
50. Yergeau, D. A., C. J. Hetherington, Q. Wang, P. Zhang, A. Sharpe, M. Binder, M. Marin-Padilla, D. G. Tenen, N. A. Speck, and D. E. Zhang. 1997. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML-ETO fusion gene. Nat. Genet. 15:303-306.